Baudax Bio Inc. [NASDAQ: BXRX] traded at a high on 10/29/20, posting a 6.60 gain after which it closed the day’ session at $1.13. The company report on October 20, 2020 that Baudax Bio Provides Commercial and Corporate Update.
ANJESO® Launch Underway; Over 50 Institutions have Added ANJESO to Their Formularies.
ANJESO Users Giving Highly Positive Feedback; Average Order Size Has Increased 75% Since Launch, Despite Ongoing COVID-related Impact to Access.
The results of the trading session contributed to over 3682305 shares changing hands. Over the past one week, the price volatility of Baudax Bio Inc. stands at 13.31% while the volatility over the past one month is 8.54%.
The market cap for BXRX stock reached $21.44 million, with 17.69 million shares outstanding and 14.45 million shares in the current float. Compared to the average trading volume of 696.07K shares, BXRX reached a trading volume of 3682305 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Baudax Bio Inc. [BXRX]?
JMP Securities have made an estimate for Baudax Bio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 15, 2020.
The Average True Range (ATR) for Baudax Bio Inc. is set at 0.21, with the Price to Sales ratio for BXRX stock in the period of the last 12 months amounting to 71.45.
How has BXRX stock performed recently?
Baudax Bio Inc. [BXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.17. With this latest performance, BXRX shares dropped by -59.21% in over the last four-week period, additionally sinking by -63.90% over the last 6 months .
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BXRX stock in for the last two-week period is set at 21.17, with the RSI for the last a single of trading hit 15.26, and the three-weeks RSI is set at 24.10 for Baudax Bio Inc. [BXRX]. The present Moving Average for the last 50 days of trading for this stock 2.7515, while it was recorded at 1.2300 for the last single week of trading, and 4.0900 for the last 200 days.
Baudax Bio Inc. [BXRX]: Deeper insight into the fundamentals
Baudax Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.10.
Insider trade positions for Baudax Bio Inc. [BXRX]
There are presently around $5 million, or 44.00% of BXRX stock, in the hands of institutional investors. The top three institutional holders of BXRX stocks are: NORTH RUN CAPITAL, LP with ownership of 1,152,539, which is approximately 0% of the company’s market cap and around 1.60% of the total institutional ownership; CORSAIR CAPITAL MANAGEMENT, L.P., holding 870,123 shares of the stock with an approximate value of $0.98 million in BXRX stocks shares; and VANGUARD GROUP INC, currently with $0.43 million in BXRX stock with ownership of nearly -9.006% of the company’s market capitalization.
24 institutional holders increased their position in Baudax Bio Inc. [NASDAQ:BXRX] by around 1,071,650 shares. Additionally, 45 investors decreased positions by around 3,368,261 shares, while 5 investors held positions by with 56,996 shares. The mentioned changes placed institutional holdings at 4,382,915 shares, according to the latest SEC report filing. BXRX stock had 19 new institutional investments in for a total of 765,382 shares, while 27 institutional investors sold positions of 2,476,611 shares during the same period.